Sensus Healthcare Plunges to Loss Amidst Revenue Decline, Soaring Costs

TL;DR

**SRTS is bleeding cash and revenue, making it a risky bet despite increased R&D spend.**

AI Summary

Sensus Healthcare, Inc. (SRTS) reported a significant decline in financial performance for the quarter ended September 30, 2025. Revenue decreased by 22.1% to $6.884 million from $8.839 million in the prior year quarter. The company swung to a net loss of $0.943 million, a stark contrast to the net income of $1.215 million reported in the same period of 2024. This resulted in a basic net loss per share of $0.06, down from a basic net income per share of $0.07. For the nine months ended September 30, 2025, revenue fell by 21.5% to $22.543 million from $28.741 million, and the company posted a net loss of $4.552 million compared to a net income of $5.101 million in the prior nine-month period. Operating expenses surged by 41.0% to $5.282 million for the quarter, driven by increases in general and administrative, selling and marketing, and research and development costs. Cash and cash equivalents increased to $24.453 million as of September 30, 2025, from $22.056 million at December 31, 2024, primarily due to net cash provided by operating activities of $2.735 million for the nine months. A significant concentration risk remains, with one U.S. customer accounting for 59% of revenue for the quarter and 86% of accounts receivable.

Why It Matters

Sensus Healthcare's sharp decline in revenue and shift to a net loss signals significant headwinds for investors, potentially impacting stock performance and future growth prospects. The substantial increase in operating expenses, particularly R&D, suggests the company is investing for future innovation, but the immediate financial results are concerning. For employees, sustained losses could lead to cost-cutting measures. Customers might see continued product development, but the company's reliance on a single major U.S. customer (59% of Q3 revenue) introduces considerable competitive risk and vulnerability to changes in that relationship, making the broader market wary of its stability.

Risk Assessment

Risk Level: high — The company reported a net loss of $0.943 million for the three months ended September 30, 2025, a significant drop from a net income of $1.215 million in the prior year. Revenue also decreased by 22.1% to $6.884 million from $8.839 million. Furthermore, a single U.S. customer accounts for 59% of revenue and 86% of accounts receivable, creating extreme customer concentration risk.

Analyst Insight

Investors should exercise extreme caution and consider reducing exposure to SRTS given the substantial revenue decline, shift to net loss, and high customer concentration risk. Await evidence of sustained revenue growth and improved profitability before considering new positions.

Financial Highlights

revenue

$6.884M

operating Margin

-37.3%

total Assets

$58.295M

total Debt

$7.101M

net Income

$(0.943)M

eps

$(0.06)

gross Margin

39.4%

cash Position

$24.453M

revenue Growth

-22.1%

Key Numbers

• $6.884M — Q3 2025 Revenue (Decreased by 22.1% from $8.839M in Q3 2024)
• $(0.943)M — Q3 2025 Net Loss (Shifted from $1.215M net income in Q3 2024)
• $(0.06) — Q3 2025 Basic Net Loss Per Share (Down from $0.07 basic net income per share in Q3 2024)
• $22.543M — Nine-Month 2025 Revenue (Decreased by 21.5% from $28.741M in nine-month 2024)
• $(4.552)M — Nine-Month 2025 Net Loss (Shifted from $5.101M net income in nine-month 2024)
• $5.282M — Q3 2025 Total Operating Expenses (Increased by 41.0% from $3.745M in Q3 2024)
• $24.453M — Cash and Cash Equivalents (As of September 30, 2025, up from $22.056M at December 31, 2024)
• 59% — Revenue Concentration (From one U.S. customer for Q3 2025)
• 86% — Accounts Receivable Concentration (From one U.S. customer as of September 30, 2025)
• $2.735M — Net Cash Provided by Operating Activities (For the nine months ended September 30, 2025)

Key Players & Entities

• Sensus Healthcare, Inc. (company) — registrant
• Sensus Healthcare Services, LLC (company) — wholly owned subsidiary
• NASDAQ Stock Market, LLC (regulator) — exchange where common stock is registered
• U.S. (regulator) — primary market for customers
• China (regulator) — foreign market for customers
• $6.884 million (dollar_amount) — total revenue for Q3 2025
• $0.943 million (dollar_amount) — net loss for Q3 2025
• $24.453 million (dollar_amount) — cash and cash equivalents as of September 30, 2025
• 59% (dollar_amount) — revenue concentration from one U.S. customer in Q3 2025
• 86% (dollar_amount) — accounts receivable concentration from one U.S. customer as of September 30, 2025

FAQ

Risk Factors

• Customer Concentration Risk [high — financial]: A significant portion of Sensus Healthcare's revenue and accounts receivable is concentrated with a single U.S. customer. For the quarter ended September 30, 2025, this customer accounted for 59% of revenue and 86% of accounts receivable. This high concentration poses a substantial risk if this customer's business or relationship with Sensus Healthcare deteriorates.

Industry Context

Sensus Healthcare operates in the medical device industry, specifically focusing on radiation oncology. The sector is characterized by long sales cycles, regulatory hurdles, and the need for continuous innovation. Companies in this space often rely on a few key customers or distributors, making customer concentration a common challenge.

Regulatory Implications

As a medical device company, Sensus Healthcare is subject to stringent regulations from bodies like the FDA. Changes in healthcare policy or reimbursement rates can significantly impact demand for its products. Compliance with evolving regulatory standards is crucial for market access and sustained operations.

What Investors Should Do

1. Monitor customer concentration closely.
2. Analyze the drivers of increased operating expenses.
3. Evaluate the sustainability of cash flow from operations.

Glossary

Operating lease right-of-use assets, net

These represent the value of a company's right to use an asset for a specified period under a lease agreement, net of accumulated amortization. This accounting change brought most leases onto the balance sheet. (Indicates the company's long-term lease commitments for assets like property or equipment.)

Deferred revenue, current portion

This represents revenue that has been received by the company but not yet earned (i.e., the goods or services have not yet been delivered or performed). The 'current portion' refers to the amount expected to be earned within the next year. (Shows unearned revenue that will be recognized as income in the near future, impacting upcoming revenue figures.)

Treasury stock

Shares of a company's own stock that it has repurchased from the open market. It is recorded at cost and reduces total stockholders' equity. (Represents shares bought back by the company, reducing the number of outstanding shares and potentially signaling management's view on the stock's valuation.)

Year-Over-Year Comparison

Compared to the prior year, Sensus Healthcare experienced a significant downturn in financial performance. Revenue for the quarter ended September 30, 2025, decreased by 22.1% to $6.884 million, and the company swung from a net income of $1.215 million to a net loss of $0.943 million. Operating expenses saw a substantial increase of 41.0% to $5.282 million, widening the operational losses. While cash reserves grew, the overall trend indicates deteriorating profitability and increased operational costs.

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share SRTS The NASDAQ Stock Mar

Filing Documents

• g085007_10q.htm (10-Q) — 821KB
• g085007_ex31-1.htm (EX-31.1) — 12KB
• g085007_ex31-2.htm (EX-31.2) — 12KB
• g085007_ex32-1.htm (EX-32.1) — 6KB
• g085007_ex32-2.htm (EX-32.2) — 6KB
• 0001753926-25-001745.txt ( ) — 4748KB
• srts-20250930.xsd (EX-101.SCH) — 28KB
• srts-20250930_cal.xml (EX-101.CAL) — 43KB
• srts-20250930_def.xml (EX-101.DEF) — 120KB
• srts-20250930_lab.xml (EX-101.LAB) — 327KB
• srts-20250930_pre.xml (EX-101.PRE) — 255KB
• g085007_10q_htm.xml (XML) — 732KB

– Financial Information

PART I – Financial Information Item 1. Condensed Consolidated Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets (unaudited) 1 Condensed Consolidated Statements of Income (Loss) (unaudited) 2 Condensed Consolidated Statements of Stockholders' Equity (unaudited) 3 Condensed Consolidated Statements of Cash Flows (unaudited) 4 Notes to the Condensed Consolidated Financial Statements (unaudited) 5 Item 2.

Management's Discussion and Analysis of Financial Condition and Results

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 24 Item 4.

Controls and Procedures

Controls and Procedures 24

– Other Information

PART II – Other Information Item 1.

Legal Proceedings

Legal Proceedings 24 Item 1A.

Risk Factors

Risk Factors 24 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosure 25 Item 5. Other Information 25 Item 6. Exhibits 26

Signatures

Signatures 27 INTRODUCTORY NOTE Forward-Looking This report includes statements that are, or may be deemed, "forward-looking statements." In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately," or "potential," or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words. Forward-looking Inc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances are consistent with the forward-looking statements contained in this report, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward looking statements contained in this report as a result of the following factors, among others: the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; th

CONDENSED CONSOLIDATED

Item 1. CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except shares and per share data) As of September 30, 2025 As of December 31, 2024 (unaudited) Assets Current assets Cash and cash equivalents $ 24,453 $ 22,056 Accounts receivable, net 9,336 19,731 Inventories 13,040 10,097 Prepaid inventory 1,341 3,347 Other current assets 2,035 1,507 Total current assets 50,205 56,738 Property and equipment, net 2,522 1,997 Deferred tax asset 4,237 2,197 Operating lease right-of-use assets, net 513 581 Other noncurrent assets 818 652 Total assets $ 58,295 $ 62,165 Liabilities and stockholders' equity Current liabilities Accounts payable and accrued expenses $ 5,619 $ 4,811 Product warranties 279 329 Operating lease liabilities, current portion 257 204 Deferred revenue, current portion 648 541 Total current liabilities 6,803 5,885 Operating lease liabilities 277 398 Deferred revenue, net of current portion 21 55 Total liabilities 7,101 6,338 Commitments and contingencies — — Stockholders' equity Preferred stock, 5,000,000 shares authorized and none issued and outstanding — — Common stock, $ 0.01 par value – 50,000,000 authorized; 17,031,845 issued and 16,440,036 outstanding at September 30, 2025; 17,036,845 issued and 16,495,396 outstanding at December 31, 2024 169 169 Additional paid-in capital 46,014 45,795 Treasury stock, 591,809 and 541,449 shares at cost, at September 30, 2025 and December 31, 2024, respectively ( 3,871 ) ( 3,571 ) Retained earnings 8,882 13,434 Total stockholders' equity 51,194 55,827 Total liabilities and stockholders' equity $ 58,295 $ 62,165 See accompanying notes to the condensed consolidated financial statements (unaudited). 1 SENSUS HEALTHCARE, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) (unaudited) For the Three Months Ended For the Nine Months Ended

View Full Filing

View this 10-Q filing on SEC EDGAR